1. Pozas M, Rodriguez M, Valls I, Soler A, Vozmediano V. Considerations about paediatric dosing: from birth to adulthood, pharmacokinetics and pharmacodynamics. Int J Pharm [Internet]. 2014;469(2):238–9. Available from:
http://www.sciencedirect.com/science/article/pii/S0378517314002853
2. Zisowsky J, Krause A, Dingemanse J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics. 2010;2(4):364–88.
3. Field MJ, Behrman RE, Children I of M (US) C on CRI. Ethical conduct of clinical research involving children. [Internet]. Washington, D.C.: National Academies Press (US); 2004. Available from:
http://www.ncbi.nlm.nih.gov/books/NBK25542/
. Accessed 31 Aug 2010.
4. European Medicines Agency ICH Topic E11: Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population (CPMP/ICH/2711/99). Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003066.pdf
. Accessed 31 Aug 2010.
5. European Commission. Ethical considerations for clinical trials on medicinal products with the paediatric population (Recommendations of the ad hoc group for the development of implementing guidelines for Directive 2001/20/EC relating to good clinical practice in the conduct. 2008. p. 1–34. Available from:
http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-10/ethical_considerations_en.pdf
.